Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a deal with Curis, a US-based oncology-focused biotechnology firm. Curis president and chief executive
The open-label trial (HPV-004) is designed to assess safety, immunogenicity, clinical responses and disease-free survival of INO-3112 in female patients with inoperable invasive cervical cancer. INO-3112 is a
Start of the Phase IIa portion of the trial follows the unanimous recommendation of the study’s Data Safety Committee after their review of all Phase Ib safety and
The partnership will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands. BIND Therapeutics chief executive officer Scott Minick said the addition of
As part of the deal, Celsion’s subsidiary CLSN Laboratories has acquired all assets and assumed certain specified liabilities of EGEN. At the closing, Celsion issued $8.5m worth of
The move will help the company to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later in 2014. Interim results for the existing AMD
The seventh ANDA filing was in connection with a current development, supply and marketing agreement with Impax Laboratories. The deal designates IGI Laboratories as the developer, manufacturer and
The drug addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized as a serious public health threat by the US Centers
The Carbapenem Resistance Consortium aims to develop a rapid diagnostic test, which can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Xpert Carba-R, which is
MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. The study,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.